🔗 Share this article

As America continues making historic revisions to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations during the pandemic and has focused upon potential deaths after COVID-19 immunization in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Immunization Schedule

Health officials had intended to announce major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of step with many the international standard with insufficient data for benefit. This reveal has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A Shift at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine centers as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a renewed priority upon rolling back previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US to become more like the Danish model, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date statements, she has persisted in emphasizing on vaccination policy – typically the purview of Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Qualifications

Høeg has little discernible track record in medication creation, oversight or administrative roles, which has been customary for former directors of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a major agency. She is not an expert in industry regulation.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who ran CBER have had.”

CDER has an vast range of responsibilities at the FDA, the former commissioner emphasized.

“Many people just pays attention on the novel medication approvals, but the generic drug division approves a multitude of generic medications. There’s a biosimilars program, OTC medication office and so forth, and each of these must be managed,” she noted. “The thing you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management element to the role, which manages more than 5,000 personnel. “It’s a enormous management job, if you execute it properly,” she concluded.

Official Statement and Contentious Initiatives

In response to inquiries about Høeg’s qualifications and whether this appointment indicates greater collaboration among agency officials on immunizations, a representative responded that the “concerns stem from flawed presumptions”.

“Her experience matches the responsibilities of her job,” the official said, citing the period Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial expedited therapy clearance system that allegedly troubled her preceding directors. “How are these therapies being chosen for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, except for shots.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a more established, if troubling, history, Howard have noted. She released a research paper using unconfirmed public submissions to assess the rate of heart inflammation after Covid immunization. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are more dangerous than they are.

Included in her “wish list” for the incoming administration included altering regulations for recently developed shots and halting “non-essential” immunizations, she said following the vote on a podcast. At the agency, Høeg has according to sources proposed excluding adolescent males from getting COVID-19 vaccines.

“She is an all-around true believer who starts off with her conclusions and works backwards to fit the data in a highly disingenuous, untruthful manner,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|